Mon compte

 

» » Etudes Cardiologie

 

 

Development of an optimized multimarker strategy

for early risk assessment of
patients with acute coronary syndromes

 

 

 

 

Lipoprotein-associated phospholipase A2
for early risk stratification in patients
with suspected acute coronary syndrome:
a multi-marker approach

 

 

 

 

Lipoprotein-Associated Phospholipase A2 Is an Independent
Marker for Coronary Endothelial Dysfunction in Humans

 

 

 

 


 

 

Lipoprotein-Associated Phospholipase A2 and Prognosis
After Myocardial Infarction in the Community

 

 

 

 

 

 

Utilisation des marqueurs cardiaques dans la maladie

coronarienne et l'insuffisance cardiaque chez l'adulte

en médecine ambulatoire

 

 

 

 

Lipoprotein-Associated Phospholipase A2: An Independent
Predictor of Coronary Artery Disease Events in Primary and
Secondary Prevention

 

 

 

 

 

 

 

Ou encore :

 

 

 

Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis

 

 

 

Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation 

 

 

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

 

 

Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study

 

 

 

Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

 

 

Lipoprotein-Associated Phospholipase A2 et évaluation du risque cardiaque